Unichem Labs Posts 52.97 Crore Profit in March Quarter
By Ankur Chandra | Updated at: May 31, 2025 07:30 PM IST
Unichem Laboratories Ltd has announced its consolidated and standalone financial results for the quarter and financial year ended March 31, 2025. The company posted a strong recovery in profitability with a sharp turnaround from the previous year’s losses.
Key Financial Highlights (₹ in Crore)
| Particulars | Q4 FY25 | Q4 FY24 | FY25 | FY24 | YoY Growth |
|---|---|---|---|---|---|
| Revenue from Operations | 587.18 | 459.60 | 2,110.97 | 1,785.11 | +18.3% |
| Total Income | 596.43 | 465.75 | 2,146.29 | 1,816.70 | +18.2% |
| EBITDA* | NA | NA | NA | NA | NA |
| Profit Before Tax (PBT) | 57.80 | (133.31) | 154.59 | (84.96) | NA |
| Net Profit / (Loss) After Tax | 52.97 | (136.74) | 137.52 | (93.76) | NA |
| Total Comprehensive Income | 46.70 | (137.54) | 130.55 | (99.41) | NA |
| EPS (Basic) – ₹ per share | 7.52 | (19.42) | 19.53 | (13.32) | NA |
*EBITDA not separately disclosed in the filing.
Segment-wise Performance
Unichem continues to operate within a single reportable segment: Pharmaceuticals. The company benefited from improved cost efficiencies and scale from its Indian manufacturing units, following the strategic closure of its UK-based Niche Generics facility.
Standalone Financials
On a standalone basis, revenue from operations stood at ₹1,735.70 crore for FY25, up from ₹1,442.16 crore in FY24. The net profit was ₹162.96 crore compared to a loss of ₹92.18 crore in the previous year.
Balance Sheet Snapshot (Consolidated)
- Total Assets: ₹3,569.40 crore (vs ₹3,274.95 crore in FY24)
- Equity: ₹2,450.59 crore
- Total Liabilities: ₹1,118.81 crore
- Cash and Cash Equivalents: ₹89.58 crore
Corporate Announcements
- Auditor Appointments:
- M/s. Kishore Bhatia & Associates re-appointed as Cost Auditors for FY26.
- M/s. Alwyn Jay & Co. appointed as Secretarial Auditor for FY26–FY30.
- M/s. Ram Agarwal & Associates re-appointed as Internal Auditor for FY26.
- Insider Trading Compliance: The Board approved the amended Code of Practices for fair disclosure under SEBI norms, to be published on the company website.
- Transferred 100% stake in Unichem Laboratories Ltd, Ireland to holding company Ipca Laboratories Ltd for ₹4 crore.
- Entered into a slump sale agreement with Bayshore Pharmaceuticals LLC (Ipca’s US subsidiary) for ANDA rights and US generics marketing business.
Management Commentary
“We are pleased with the robust turnaround in our financial performance. Strategic consolidation of international operations and leveraging our India manufacturing base have enabled better margins. We continue to remain focused on compliance, R&D, and global market expansion,” said Pabitrakumar Bhattacharyya, Managing Director.
Strategic Outlook
Unichem aims to optimize manufacturing efficiency by centralizing operations in India while expanding its US generics portfolio through acquired ANDAs. Despite the one-time EU fine provision impacting FY24, the company enters FY26 with improved financial stability, healthy reserves, and an optimistic business pipeline.
- Dividend: No dividend announcement was made for FY25.
- Audit Opinion: The statutory auditors, N.A. Shah Associates LLP, have issued an unmodified opinion on the financial results.
Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. The content is based on highly reliable resources. Still if there is any error it is deeply regretted. Write to us for getting any error corrected.
REF: https://nsearchives.nseindia.com/corporate/HIRALMEHTA_22052025141051_OutComeOfBoardMeeting.pdf
